BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Madsen MSA, Holm JB, Pallejà A, Wismann P, Fabricius K, Rigbolt K, Mikkelsen M, Sommer M, Jelsing J, Nielsen HB, Vrang N, Hansen HH. Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep 2019;9:15582. [PMID: 31666597 DOI: 10.1038/s41598-019-52103-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Abdalqadir N, Adeli K. GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk. Microorganisms 2022;10:2061. [DOI: 10.3390/microorganisms10102061] [Reference Citation Analysis]
2 Wu L, Gao Y, Su Y, Li J, Ren W, Wang Q, Kuang H. Probiotics with anti-type 2 diabetes mellitus properties: targets of polysaccharides from traditional Chinese medicine. Chinese Journal of Natural Medicines 2022;20:641-55. [DOI: 10.1016/s1875-5364(22)60210-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wong CK, Yusta B, Koehler JA, Baggio LL, McLean BA, Matthews D, Seeley RJ, Drucker DJ. Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation. Cell Metab 2022:S1550-4131(22)00346-1. [PMID: 36027914 DOI: 10.1016/j.cmet.2022.08.003] [Reference Citation Analysis]
4 Kroscher KA, Fausnacht DW, McMillan RP, El-Kadi SW, Wall EH, Bravo DM, Rhoads RP. Supplementation with artificial sweetener and capsaicin alters metabolic flexibility and performance in heat-stressed and feed-restricted pigs. J Anim Sci 2022;100:skac195. [PMID: 35908791 DOI: 10.1093/jas/skac195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sacerdote A. Rare and Underappreciated Causes of Polycystic Ovarian Syndrome. Polycystic Ovary Syndrome - Functional Investigation and Clinical Application 2022. [DOI: 10.5772/intechopen.101946] [Reference Citation Analysis]
6 Meiring S, van Baar ACG, Sørensen N, Holleman F, Soeters MR, Nieuwdorp M, Bergman JJGHM. A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study. Front Clin Diabetes Healthc 2022;3. [DOI: 10.3389/fcdhc.2022.856661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chen F, He L, Li J, Yang S, Zhang B, Zhu D, Wu Z, Zhang S, Hou D, Ouyang C, Yi J, Xiao C, Hou K. Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota. Front Mol Biosci 2022;9:879294. [DOI: 10.3389/fmolb.2022.879294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Moon JS, Hong JH, Jung YJ, Ferrannini E, Nauck MA, Lim S. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2022;33:424-42. [PMID: 35491295 DOI: 10.1016/j.tem.2022.03.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Bastos RMC, Simplício-Filho A, Sávio-Silva C, Oliveira LFV, Cruz GNF, Sousa EH, Noronha IL, Mangueira CLP, Quaglierini-Ribeiro H, Josefi-Rocha GR, Rangel ÉB. Fecal Microbiota Transplant in a Pre-Clinical Model of Type 2 Diabetes Mellitus, Obesity and Diabetic Kidney Disease. Int J Mol Sci 2022;23:3842. [PMID: 35409202 DOI: 10.3390/ijms23073842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Oliveira FCB, Bauer EJ, Ribeiro CM, Pereira SA, Beserra BTS, Wajner SM, Maia AL, Neves FAR, Coelho MS, Amato AA. Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue. Front Endocrinol (Lausanne) 2021;12:803363. [PMID: 35069450 DOI: 10.3389/fendo.2021.803363] [Reference Citation Analysis]
11 Aron-wisnewsky J, Lefevre C, Bindels LB. Interactions entre les traitements du diabète et le microbiote intestinal : état des connaissances et perspectives. Médecine des Maladies Métaboliques 2022;16:148-159. [DOI: 10.1016/j.mmm.2022.01.004] [Reference Citation Analysis]
12 Craciun C, Neag M, Catinean A, Mitre A, Rusu A, Bala C, Roman G, Buzoianu A, Muntean D, Craciun A. The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus. Biomedicines 2022;10:308. [DOI: 10.3390/biomedicines10020308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Madla CM, Gavins FKH, Trenfield SJ, Basit AW. Special Populations. Biopharmaceutics 2022. [DOI: 10.1002/9781119678366.ch13] [Reference Citation Analysis]
14 Ma J, Wang J, Xu L, Liu Y, Gu J. The beneficial effects of genetically engineered Escherichia coli Nissle 1917 in obese C57BL/6J mice. Int J Obes. [DOI: 10.1038/s41366-022-01073-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Bastos RM, Rangel ÉB. Gut microbiota-derived metabolites are novel targets for improving insulin resistance. World J Diabetes 2022; 13(1): 65-69 [DOI: 10.4239/wjd.v13.i1.65] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Tsai C, Lu H, Chou Y, Liu P, Chen H, Huang M, Lin C, Tsai C. Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study. Front Endocrinol 2022;12:814770. [DOI: 10.3389/fendo.2021.814770] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Hori M, Hasegawa Y, Hayashi Y, Nakagami T, Harada-shiba M. Acute Cholesterol-Lowering Effect of Exendin-4 in <i>Ldlr</i><sup>−/−</sup> and C57BL/6J Mice. JAT. [DOI: 10.5551/jat.60921] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Sharma VK, Singh TG, Dhiman S, Garg N. Mechanisms of Beneficial Effects of Probiotics in Diabetes Mellitus. Probiotic Research in Therapeutics 2022. [DOI: 10.1007/978-981-16-8444-9_6] [Reference Citation Analysis]
19 Chen Y, Wang M. New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes. Drug Des Devel Ther 2021;15:4849-63. [PMID: 34876807 DOI: 10.2147/DDDT.S334325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Koike M, Saito H, Kohno G, Takubo M, Watanabe K, Ishihara H. Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages. Int J Mol Sci 2021;22:11463. [PMID: 34768897 DOI: 10.3390/ijms222111463] [Reference Citation Analysis]
21 Merkevičius K, Kundelis R, Maleckas A, Veličkienė D. Microbiome Changes after Type 2 Diabetes Treatment: A Systematic Review. Medicina (Kaunas) 2021;57:1084. [PMID: 34684121 DOI: 10.3390/medicina57101084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ferrier L, Eutamène H, Siegwald L, Marquard AM, Tondereau V, Chevalier J, Jacot GE, Favre L, Theodorou V, Vicario M, Rytz A, Bergonzelli G, Garcia-Rodenas CL. Human milk oligosaccharides alleviate stress-induced visceral hypersensitivity and associated microbiota dysbiosis. J Nutr Biochem 2022;99:108865. [PMID: 34582967 DOI: 10.1016/j.jnutbio.2021.108865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Schupack DA, Mars RAT, Voelker DH, Abeykoon JP, Kashyap PC. The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34453142 DOI: 10.1038/s41575-021-00499-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
24 Long LL, Svenson KL, Mourino AJ, Michaud M, Fahey JR, Waterman L, Vandegrift KL, Adams MD. Shared and distinctive features of the gut microbiome of C57BL/6 mice from different vendors and production sites, and in response to a new vivarium. Lab Anim (NY) 2021;50:185-95. [PMID: 34127866 DOI: 10.1038/s41684-021-00777-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
25 Wang L, Chen T, Wang H, Wu X, Cao Q, Wen K, Deng KY, Xin H. Engineered Bacteria of MG1363-pMG36e-GLP-1 Attenuated Obesity-Induced by High Fat Diet in Mice. Front Cell Infect Microbiol 2021;11:595575. [PMID: 33732656 DOI: 10.3389/fcimb.2021.595575] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
26 Khudhair Z, Alhallaf R, Eichenberger RM, Whan J, Kupz A, Field M, Krause L, Wilson DT, Daly NL, Giacomin P, Sotillo J, Loukas A. Gastrointestinal Helminth Infection Improves Insulin Sensitivity, Decreases Systemic Inflammation, and Alters the Composition of Gut Microbiota in Distinct Mouse Models of Type 2 Diabetes. Front Endocrinol (Lausanne) 2020;11:606530. [PMID: 33613446 DOI: 10.3389/fendo.2020.606530] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
27 Knudsen JK, Leutscher P, Sørensen S. Gut Microbiota in Bone Health and Diabetes. Curr Osteoporos Rep 2021;19:462-79. [PMID: 33523423 DOI: 10.1007/s11914-020-00629-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
28 Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Adv Cancer Res 2021;149:171-255. [PMID: 33579424 DOI: 10.1016/bs.acr.2020.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
29 Madsen MSA, Grønlund RV, Eid J, Christensen-Dalsgaard M, Sommer M, Rigbolt K, Madsen MR, Jelsing J, Vrang N, Hansen HH, Mikkelsen M. Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice. Biomed Pharmacother 2021;133:110966. [PMID: 33171401 DOI: 10.1016/j.biopha.2020.110966] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
30 Thottapillil A, Kouser S, Kukkupuni SK, Vishnuprasad CN. An 'Ayurveda-Biology' platform for integrative diabetes management. J Ethnopharmacol 2021;268:113575. [PMID: 33181283 DOI: 10.1016/j.jep.2020.113575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
31 Li M, Zhou W, Dang Y, Li C, Ji G, Zhang L. Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice. Biomed Pharmacother 2020;132:110953. [PMID: 33254441 DOI: 10.1016/j.biopha.2020.110953] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
32 Ding QY, Tian JX, Li M, Lian FM, Zhao LH, Wei XX, Han L, Zheng YJ, Gao ZZ, Yang HY, Fang XY, Tong XL. Interactions Between Therapeutics for Metabolic Disease, Cardiovascular Risk Factors, and Gut Microbiota. Front Cell Infect Microbiol 2020;10:530160. [PMID: 33194785 DOI: 10.3389/fcimb.2020.530160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Cha KH, Yang J, Kim K, Yoon K, Song D, Erdene-ochir E, Kang K, Pan C, Ko G. Improvement in host metabolic homeostasis and alteration in gut microbiota in mice on the high-fat diet: A comparison of calcium supplements. Food Research International 2020;136:109495. [DOI: 10.1016/j.foodres.2020.109495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Cao TTB, Wu KC, Hsu JL, Chang CS, Chou C, Lin CY, Liao YM, Lin PC, Yang LY, Lin HW. Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies. Front Endocrinol (Lausanne) 2020;11:573891. [PMID: 33071980 DOI: 10.3389/fendo.2020.573891] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
35 Stemmer K, Finan B, DiMarchi RD, Tschöp MH, Müller TD. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. Adv Drug Deliv Rev 2020;159:34-53. [PMID: 32485206 DOI: 10.1016/j.addr.2020.05.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
36 Park S, Zhang T, Qiu JY, Wu X, Lee JY, Lee BY. Acid Hydrolyzed Silk Peptide Consumption Improves Anti-Diabetic Symptoms by Potentiating Insulin Secretion and Preventing Gut Microbiome Dysbiosis in Non-Obese Type 2 Diabetic Animals. Nutrients 2020;12:E311. [PMID: 31991596 DOI: 10.3390/nu12020311] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]